Table 1.
Susceptibility profile to erythromycin and clindamycin of susceptible and methicillin-resistant S. aureus and CNS.
| Phenotypes | MSSA n (%) |
MRSA n (%) |
MSCNS n (%) |
MRCNS n (%) |
Total n (%) |
|---|---|---|---|---|---|
| ERY-S, CLI-S (susceptible) | 25 (67.6) | 5 (22.7) | 4 (28.6) | 7 (23.3) | 41 (39.8) |
| ERY-S, CLI-I | 1 (2.7) | 0 (0) | 1 (7.1) | 0 (0) | 2 (1.9) |
| ERY-S, CLI-R | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ERY-I, CLI-S | 1 (2.7) | 0 (0) | 2 (14.3) | 0 (0) | 3 (2.9) |
| ERY-I, CLI-I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ERY-I, CLI-R | 0 (0) | 0 (0) | 0 (0) | 1 (3.3) | 1 (1) |
| ERY-R, CLI-R (cMLSB) | 4 (10.8) | 15 (68.2) | 3 (21.4) | 17 (56.7) | 39 (37.9) |
| ERY-R, CLI-S/I, + D Test (iMLSB) | 4 (10.8) | 1 (4.5) | 0 (0) | 0 (0) | 5 (4.9) |
| ERY-R, CLI-S/I, – Test D (MSB) | 2 (5.4) | 1 (4.5) | 4 (28.6) | 5 (16.7) | 12 (11.6) |
| Total | 37 (35.9) | 22 (21.4) | 14 (13.6) | 30 (29.1) | 103 (100) |
ERY, erythromycin; CLI, clindamycin; S, susceptible; I, intermediary; R, resistant; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; MSCNS, methicillin-susceptible coagulase-negative Staphylococcus; MRCNS, methicillin-resistant coagulase-negative Staphylococcus; MLSB, macrolides, lincosamides and type B streptogramins; cMLSB, phenotype of constitutive MLSB resistance; iMLSB, phenotype of inducible MLSB resistance; MSB, phenotype of resistance to macrolides and type B streptogramins.